Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company's products under development include BonoFill for the treatment of bone tissue regeneration in maxillofacial and orthopedic indications, and defects in limb and jaw bones which is in Phase II clinical trial, as well as in a preclinical stage for the treatment of bone augmentation in osteoporosis patients. It also develops MesenCure for the treatment of COVID patients suffering from pneumonia and ARDS which is in phase III clinical trial, as well as in preclinical stage for the treatment of other inflammations and tissue damage, including chronic kidney diseases, osteoarthritis, and cytokine release syndrome. The company was formerly known as Oceana Advanced Industries Ltd. Bonus BioGroup Ltd. was incorporated in 1981 and is headquartered in Haifa, Israel.
Frequently asked questions
What sector does Bonus BioGroup Ltd (BBIXF) operate in?
Bonus BioGroup Ltd belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Bonus BioGroup Ltd (BBIXF) current stock price?
As of the latest data, Bonus BioGroup Ltd stock price is $0.04, with a previous close of $0.04.
What is Bonus BioGroup Ltd (BBIXF) current market capitalization?
Bonus BioGroup Ltd market cap is approximately 46.72 million.
What is Bonus BioGroup Ltd (BBIXF) Earnings Per Share (EPS)?
The trailing EPS is -$0.01.
What is Bonus BioGroup Ltd (BBIXF) EBITDA?
Bonus BioGroup Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -5.11 million.
Does Bonus BioGroup Ltd (BBIXF) pay dividends?
No. Bonus BioGroup Ltd does not pay a dividend.
What is Bonus BioGroup Ltd (BBIXF) beta (volatility) score?
Bonus BioGroup Ltd has a beta of 0.844, meaning its volatility is roughly in line with the market.
